R&D Six things we learned about the obesity market at LSX 2025 In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.
News After internal setbacks, Pfizer buys obesity player Metsera Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.
News Closed Loop Medicine launches digital GLP-1 dosing platform Closed Loop Medicine has launched its first product in the US, a digital tool for personalising the dose of GLP-1 weight-loss therapies.
News Oral GLP-1 contest ramps up with new Novo Nordisk data Novo Nordisk has trumpeted data showing oral Wegovy matched the injectable version in a phase 3 trial, ramping up pressure on rival Eli Lilly.
News Lilly weakens on data reveal for oral obesity candidate Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.
News Study finds Novo's Wegovy turns down 'food noise' Novo Nordisk has said a real-world survey of Wegovy shows it can reduce 'food noise', persistent, intrusive, or repetitive thoughts about eating.
News NHS use of digital cardiac rehab tools endorsed Seven digital health technologies used to support people recovering from cardiovascular diseases have been recommended for use by the NHS.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.